X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Potassium Chloride API
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2021
Details:
Nexus Pharmaceuticals has announced that it has received U.S. FDA approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Potassium Chloride API
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
The Potassium Chloride product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Potassium Chloride for Oral Solution USP, 20 mEq, of Pharma Research Software Solution, LLC.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anamorelin HCl
Therapeutic Area: Nutrition and Weight Loss Product Name: Adlumiz
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2021
Details:
Marketing approval of Adlumiz® (generic name: anamorelin hydrochloride) Tablet 50mg (“Adlumiz”) is mainly based on the results from the ONO-7643-04 and ONO-7643-05 studies conducted in Japan in patients with cancer cachexia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Deoxycholic Acid
Therapeutic Area: Nutrition and Weight Loss Product Name: Kybella
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: SWK Holdings Corporation
Deal Size: $4.3 million Upfront Cash: $4.3 million
Deal Type: Divestment August 31, 2020
Details:
Under the terms of the definitive agreement, PDL BioPharma will sale three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK Funding, LLC a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mirtazapine
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Dechra Pharmaceuticals Manufacturing
Deal Size: Undisclosed Upfront Cash: $43.0 million
Deal Type: Divestment March 16, 2020
Details:
The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
